Analysis of the causes and predictive factors for discontinuing treatment with tenofovir in pretreated HIV patients;Análisis de las causas y factores predictivos de discontinuación del tratamiento con tenofovir en pacientes VIH pretratados

Farmacia Hospitalaria

Volumn 31, Issue 4, 2007, Pages 200-205

  Morillo Verdugo, Ramón ^a,d   Gil Navarro, M V ^b   Abdel Kader Martin L ^a   Castillo Munoz A ^b   Banos Roldan U ^c   Artacho Criado, S ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d NONE   (Spain)

Author keywords

Adverse effects; HAART; HIV; Predictive factors; Tenofovir

Indexed keywords

ANTIRETROVIRUS AGENT; CREATININE; TENOFOVIR;

ADULT; ANAMNESIS; ARTICLE; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DIARRHEA; DRUG WITHDRAWAL; FEMALE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL PHARMACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; RISK FACTOR; SOCIAL ASPECT; SURVIVAL; TREATMENT DURATION; TREATMENT FAILURE; VOMITING;

EID: 36349009270     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(07)75374-6     Document Type: Article

References (29)

1. Iribarren JA, Labarga P, Rubio R, Berenguer J, Miró JM, Antela A, et al. Recomendaciones de GESIDA/PNS respecte al tratamiento antirretroviral en patientes adultos infectados por el virus de la inmunodeficiencia humana (enero 2007). Enferm Infecc Microbiol Clin 2007; 25: 32-53.
2. Escobar I, Knobel H, Polo R, Ortega L, Martín Conde MT, Casado JL, et al. Recomendaciones GESIDA/SEFH/PNS para mejorar la adherencia al tratamiento antirretroviral en el año 2004. Farm Hosp 2004 (Supl. 1): 6-18.
3. Panel on Clinical Practices for Treatment of HIV infection convened by the U.S. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, (citado 17-01-2007). Disponible en: http://www.aidsinfo.nih.gov/contentfiles/ adultandadolescentGL.pdf.
4. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity an mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
5. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patient infected with HIV-1. EuroSIDA study group. Lancet 1998; 352: 1725-30.
6. Mocroft A, Youle M, Moore A, Sabin C, Madge S, Cozzi A, et al. Reasons for modification and discontinuation of antiretrovirals: result from a single treatment centre. AIDS 2001; 15: 185-94.
7. Gallant JE, Staszewski S, Pozniak AL, Dejesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201.
8. Schooley RT, Ruane P, Myers R, Beall G, Lampiris H, Berger D, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48 week, randomized, double-blind study. AIDS 2002; 16: 1257-63.
9. Lyseng-Williamson KA, Reynolds NA, Plosker GL. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs 2005; 65: 413-32.
10. Hoogewerf M, Regez R, Schouten W, Weigel H, Frissen P, Brinman K. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet 2003; 362: 1979-80.
11. Buehlmann M, Chave JP, Flepp M, Schiffer V, Keiser O, Furrer H. Tenofovir-containing nucleoside/nucleotide-only antiretroviral maintenance therapy: decision making and virological outcome. HIV Clin Trials 2006; 7: 48-54.
12. Karra A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni S, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patient: Three cases of renal failure, Fancony sindrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 1070-3.
13. Rollot F, Nazal E, Chauvelot-Moachon L, Kelaidi C, Daniel N, Saba M, et al. Tenofovir-related Fancony sindrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: The role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003; 37: e174-6.
14. Gallant J, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40: 1194-8.
15. Schaaf B, Aries SP, Kramme E, Steinhoff J, Dalhoff K. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infec Dis 2003; 37: e41-3.
16. Callens S, De Roo A, Colebunders R. Fancony-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J Infect 2003; 47: 262-3.
17. Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launav-Vacher V, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005; 20: 743-6.
18. Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Mandalia S, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr 2004; 37: 1489-95.
19. Nota informativa de la Agencia Española de Medicamentos y Productos Sanitarios: Administración de didanosina y tenofovir: Nuevos dates de eficacia y seguridad desaconsejan su uso concomitante. (citado 19-07-2006). Disponible en: www.agemed.es/actividad/alertas/usoHumano/seguridad/didanosina. htm
20. Nota informativa de la Agencia Española de Medicamentos y Productos Sanitarios: Falta de respuesta virológica prematura en pacientes con infección por VIH tratados con tenofovir en combinación con lamivudina y abacavir. (citado 19-07-2006). Disponible en: www.age-med.es/ actividad/alertas/usoHumano/seguridad/tenofovir.htm
21. Squires K, Pozniak A, Pierone G, Steinhart CR, Berger D, Bellos NC, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection. Ann Intern Med 2003; 139: 313-20.
22. D'arminio-Monforte A, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC, et al. Clinical outcome of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998; 12: 1631-7.
23. D'arminio-Monforte A, Cozzi A, Rezza G, Pezzotti P, Antinori A, Phillips A, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000; 14: 499-507.
24. Nelson M, Cooper D, Schooley R, Katlama C, Montaner J, Curtis S, et al. The safety of tenofovir DF for the treatment of HIV infection: The first four years. In: 13th Conference on retroviruses and Opportunistic Infections; February 5-8, 2006. Denver. Abstract 781.
25. Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, et al. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS 2004; 17: 2333-5.
26. Zimmermann A, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interaction. Clin Infec Dis 2006; 42: 283-90.
27. Izzedine H, Isnard-Bagnis C, Hulot JS, Vittecoq D, Cheng A, Kreft C, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 7: 1014-6.
28. Spire B, Carrieri P, Garzot MA, L'henaff M, Obadia Y. Factors associated with efavirenz discontinuation in a large community-based simple of patients. AIDS care 2004; 16: 558-64.
29. Bongiovanni M, Cicconi P, Landonio S, Meraviglia P, Testa L, di Biagio A, et al. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: Results from a cohort of 416 multi-experienced HIV-infected individuals. Int J Antimicrob Agents 2005; 26: 88-91.